Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561906
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-16
Brief Title:
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI Behavioral Genetic and Plasma Biomarkers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI Behavioral Genetic and Plasma Biomarkers
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline demographic cognitive behavioral multimodal MRI genetic and plasma data
Detailed Description:
Alzheimers disease AD is a global concern Due to the lack of effective therapeutic methods targeting late-stage AD patients it is critical to investigate brain alterations in the preclinical stage to pave the way for early diagnosis and intervention Structural and functional magnetic resonance imaging MRI has been proven to be an effective and non-invasive approach to explore the neural mechanisms underlying neurological disorders Genetic factors such as apolipoprotein E and plasma biomarkers play important roles in AD development and progression However the interaction effects of risk genes and different pathologic pathways implicated in the pathogenesis of AD remain unclear Furthermore the diagnostic and prognostic models that could predict future cognitive decline or clinical progression based on objective features derived from baseline demographic cognitive behavioral multimodal MRI genetic and plasma data need to be further explored
We aim to investigate the neural basis underlying early cognitive deficits using structural and functional MRI data combined with novel analytical methods such as dynamic functional connectivity surface-based morphometry graph theory multilayer network functional-structural coupling hidden Markov model and connectome gradient mapping Secondly to explore the interaction effects of risk genes which may help a better illustration of different biological pathways implicated in the pathogenesis of Alzheimers disease Thirdly to investigate the divergent and dynamic abnormalities of multimodal imaging markers across different stages of Alzheimers disease and their associations with plasma biomarkers which may enhance our understanding of the neuropathological mechanisms Fourthly to provide scientific evidence on the potential targets for early intervention of neurodegenerative diseases Lastly to establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline multimodal biomarkers These studies may help a better understanding of the neural and biological basis underlying AD and pave the way for early diagnosis and intervention
We aim to investigate the neural basis underlying early cognitive deficits using structural and functional MRI data combined with novel analytical methods such as dynamic functional connectivity surface-based morphometry graph theory multilayer network functional-structural coupling hidden Markov model and connectome gradient mapping Secondly to explore the interaction effects of risk genes which may help a better illustration of different biological pathways implicated in the pathogenesis of Alzheimers disease Thirdly to investigate the divergent and dynamic abnormalities of multimodal imaging markers across different stages of Alzheimers disease and their associations with plasma biomarkers which may enhance our understanding of the neuropathological mechanisms Fourthly to provide scientific evidence on the potential targets for early intervention of neurodegenerative diseases Lastly to establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline multimodal biomarkers These studies may help a better understanding of the neural and biological basis underlying AD and pave the way for early diagnosis and intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None